Citadel Advisors’s Park Ha Biological Technology Co BYAH Stock Holding History

Citadel Advisors’s Portfolio BYAH Stock Details BYAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-235	Closed	-$14.9K	–	14484
2025 Q4	$14.9K	Buy	+235	New	+$28.5K	﹤0.01%	12398
2025 Q3	–	Sell	-53	Closed	-$743K	–	14393
2025 Q2	$743K	Buy	53 +11	+26%	+$73.9K	﹤0.01%	7724
2025 Q1	$220K	Sell	42 -32	-43%	-$87.1K	﹤0.01%	10274
2024 Q4	$187K	Buy	+74	New	+$150K	﹤0.01%	10562

Other funds holding BYAH

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's BYAH Position: Q1 2026 in Review

Citadel Advisors sold out of Park Ha Biological Technology Co (BYAH) in Q1 2026, closing a stake of 235 shares — an estimated $14.9K sold.

Citadel Advisors first reported a position in BYAH in Q4 2024 and held it in 4 quarters. The position peaked at $743K in Q2 2025. 2 funds tracked by Wall St. Rank hold BYAH as of Q1 2026.

Citadel Advisors reported no remaining Park Ha Biological Technology Co position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 235 Park Ha Biological Technology Co shares in Q1 2026, an estimated $14.9K.
Citadel Advisors first reported a position in Park Ha Biological Technology Co in Q4 2024 and held it in 4 quarters.
Citadel Advisors's Park Ha Biological Technology Co position peaked at $743K in Q2 2025.
2 funds tracked by Wall St. Rank held Park Ha Biological Technology Co as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.